Biological and clinical implications of EGFR mutations in lung cancer

International Journal of Clinical Oncology

Volumn 11, Issue 3, 2006, Pages 190-198

  Mitsudomi, Tetsuya ^a   Kosaka, Takayuki ^a   Yatabe, Yasushi ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Gefitinib; Individualized therapy; Molecular targeted therapy; Predictive factor; Tyrosine kinase inhibitor

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; B RAF KINASE; BCR ABL PROTEIN; BIOLOGICAL MARKER; CANERTINIB; CARBOPLATIN; CISPLATIN; CL 387785; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ETOPOSIDE; GEFITINIB; IMATINIB; K RAS PROTEIN; LAPATINIB; PACLITAXEL; PELITINIB; PLATELET DERIVED GROWTH FACTOR A; PLATINUM; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR; SU 11464; UNCLASSIFIED DRUG; VANDETANIB;

BIOLOGICAL ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GENETICS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TARGETING; ETHNOLOGY; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; HUMAN; INTERMETHOD COMPARISON; LUNG CANCER; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG SURGERY; MEDICAL LITERATURE; MOLECULAR EPIDEMIOLOGY; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PATHOLOGY; PATIENT SELECTION; POINT MUTATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SMOKING; SURVIVAL TIME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33746133158     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-006-0583-4     Document Type: Review

References (67)

1. JH Schiller D Harrington CP Belani 2002 Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 92 98
2. CL Arteaga 2002 Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia Semin Oncol 29 3 9
3. F Ciardiello G Tortora 2001 A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor Clin Cancer Res 7 2958 2970
4. M Fukuoka S Yano G Giaccone 2003 Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer J Clin Oncol 21 2237 2246
5. MG Kris RB Natale RS Herbst 2003 Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial JAMA 290 2149 2158
6. VA Miller MG Kris N Shah 2004 Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer J Clin Oncol 22 1103 1109
7. F Cappuzzo V Gregorc E Rossi 2003 Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC J Clin Oncol 21 2658 2663
8. T Suzuki T Nakagawa H Endo 2003 The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ("Iressa") is not related to the expression of EGFR or HER-2 or to K-ras gene status Lung Cancer 42 35 41
9. JG Paez PA Janne JC Lee 2004 EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 1497 1500
10. TJ Lynch DW Bell R Sordella 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2129 2139
11. R Sordella DW Bell DA Haber 2004 Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways Science 305 1163 1167
12. H Suzuki T Takahashi T Kuroishi 1992 p53 mutations in non-small cell lung cancer in Japan: Association between mutations and smoking Cancer Res 52 734 736
13. SA Ahrendt PA Decker EA Alawi 2001 Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung Cancer 92 1525 1530
14. T Mitsudomi T Oyama K Nishida 1996 Loss of heterozygosity at 3p in non-small cell lung cancer and its prognostic implication Clin Cancer Res 2 1185 1189
15. T Kosaka Y Yatabe H Endoh 2004 Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications Cancer Res 64 8919 8923
16. NL Kobrinsky MG Klug PJ Hokanson 2003 Impact of smoking on cancer stage at diagnosis J Clin Oncol 21 907 913
17. W Liu F Innocenti P Chen 2003 Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism Clin Cancer Res 9 1009 1012
18. F Gebhardt KS Zanker B Brandt 1999 Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1 J Biol Chem 274 13176 13180
19. Y Yatabe T Kosaka T Takahashi 2005 EGFR mutation is specific for terminal respiratory unit type adenocarcinoma Am J Surg Pathol 29 633 639
20. A Marchetti C Martella L Felicioni 2005 EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment J Clin Oncol 23 857 865
21. H Shigematsu L Lin T Takahashi 2005 Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers J Natl Cancer Inst 97 339 346
22. H Shigematsu AF Gazdar 2006 Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers Int J Cancer 118 257 262
23. T Mitsudomi T Kosaka H Endoh 2005 Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence J Clin Oncol 23 2513 2520
24. SW Han TY Kim PG Hwang 2005 Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib J Clin Oncol 23 2493 2501
25. KS Kim JY Jeong YC Kim 2005 Predictors of the response to gefitinib in refractory non-small cell lung cancer Clin Cancer Res 11 2244 2251
26. H Cortes-Funes C Gomez R Rosell 2005 Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients Ann Oncol 16 1081 1086
27. M Taron Y Ichinose R Rosell 2005 Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas Clin Cancer Res 11 5878 5885
28. T Takano Y Ohe H Sakamoto 2005 Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer J Clin Oncol 23 6829 6837
29. GJ Riely W Pao D Pham 2006 Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib Clin Cancer Res 12 839 844
30. H Greulich T-H Chen W Feng 2005 Oncogenic transformation by inhibitor-sensitive and resistant EGFR mutations PLoS Med 2 e313
31. F Cappuzzo FR Hirsch E Rossi 2005 Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer J Natl Cancer Inst 97 643 655
32. MS Tsao A Sakurada JC Cutz 2005 Erlotinib in lung cancer - molecular and clinical predictors of outcome N Engl J Med 353 133 144
33. T Shibata S Uryu A Kokubu 2005 Genetic classification of lung adenocarcinoma based on array-based comparative genomic hybridization analysis: its association with clinicopathologic features Clin Cancer Res 11 6177 6185
34. F Cappuzzo E Magrini GL Ceresoli 2004 Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer J Natl Cancer Inst 96 1133 1141
35. F Cappuzzo M Varella-Garcia H Shigematsu 2005 Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients J Clin Oncol 23 5007 5018
36. W Pao TY Wang GJ Riely 2005 KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib PLoS Med 2 e17
37. S Kobayashi TJ Boggon T Dayaram 2005 EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N Engl J Med 352 786 792
38. W Pao VA Miller KA Politi 2005 Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med 2 e73
39. NP Shah JM Nicoll B Nagar 2002 Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia Cancer Cell 2 117 125
40. ME Gorre M Mohammed K Ellwood 2001 Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 293 876 880
41. S Blencke A Ullrich H Daub 2003 Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors J Biol Chem 278 15435 15440
42. TA Carter LM Wodicka NP Shah 2005 Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases Proc Natl Acad Sci USA 102 11011 11016
43. RS Herbst D Prager R Hermann 2005 TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 23 5892 5899
44. FA Shepherd J Rodrigues Pereira T Ciuleanu 2005 Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 123 132
45. Thatcher N, Chang A, Parikh P (2005) Results of a Phase III placebo-controlled study (ISEL) of gefitinib (IRESSA) plus best supportive care (BSC) in patients with advanced non-cmall-cell lung cancer (NSCLC) who had received 1 or 2 prior chemotherapy regimens. Proc Am Assoc Cancer Res 46 (suppl): Abstract# LB-6
46. T Takano Y Ohe M Kusumoto 2004 Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib Lung Cancer 45 93 104
47. DW Bell TJ Lynch SM Haserlat 2005 Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials J Clin Oncol 23 8081 8092
48. FR Hirsch M Varella-Garcia J [tmp] McCoy 2005 Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study J Clin Oncol 23 6838 6845
49. G Giaccone RS Herbst C Manegold 2004 Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1 J Clin Oncol 22 777 784
50. RS Herbst G Giaccone JH Schiller 2004 Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2 J Clin Oncol 22 785 794
51. N Thatcher A Chang P Parikh 2005 Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 1527 1537
52. R Perez-Soler 2004 Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer Clin Lung Cancer 6 Suppl 1 S20 S23
53. H Kaneda K Tamura T Kurata 2004 Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer Lung Cancer 46 247 254
54. SF Huang HP Liu LH Li 2004 High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan Clin Cancer Res 10 8195 8203
55. Kris MG, Sandler A, Miller V, et al. (2004) Cigarette smoking history predicts sensitivity to erlotinib: results of a phase II trial in patients with bronchioloalveolar carcinoma (BAC). J Clin Oncol 22:Abstract# 7062
56. ST Lim EH Wong KL Chuah 2005 Gefitinib is more effective in never-smokers with non-small-cell lung cancer: experience among Asian patients Br J Cancer 93 23 28
57. DH Lee JY Han HG Lee 2005 Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers Clin Cancer Res 11 3032 3037
58. XT Zhang LY Li XL Mu 2005 The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer Ann Oncol 16 1334 1342
59. M Tokumo S Toyooka K Kiura 2005 The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers Clin Cancer Res 11 1167 1173
60. W Pao V Miller M Zakowski 2004 EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci USA 101 13306 13311
61. SH Yang LE Mechanic P Yang 2005 Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer Clin Cancer Res 11 2106 2110
62. YH Soung JW Lee SY Kim 2005 Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas Virchows Arch 446 483 488
63. BM Qin X Chen JD Zhu 2005 Identification of EGFR kinase domain mutations among lung cancer patients in China: implication for targeted cancer therapy Cell Res 15 212 217
64. TY Chou CH Chiu LH Li 2005 Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer Clin Cancer Res 11 3750 3757
65. M Sonobe T Manabe H Wada 2005 Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma Br J Cancer 93 355 363
66. XL Mu LY Li XT Zhang 2005 Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in Chinese patients with non-small cell lung cancer Clin Cancer Res 11 4289 4294
67. Y Tomizawa H Iijima N Sunaga 2005 Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer Clin Cancer Res 11 6816 6822